| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer
1 company
Collins Helen Louise is a Chief Medical Officer at ELVN. Recent filings cover 0 purchases and 27 sales. Those positions are worth an estimated $962K at current prices.
Our model assigns Collins Helen Louise a middling insider score of 64/100, based on 5 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +28.4%.
Collins Helen Louise's largest disclosed position is in ELVN as Chief Medical Officer, worth about $962K. The recent filings there lean toward selling, a net 185,816 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 45,000 | $26.17 | $1,177,861.50 | -64.3% | +51.7% | - | |
| Oct 18, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 816 | $30.00 | $24,482.45 | - | -24.2% | -26.2% | |
| Apr 11, 2024 | ELVN Enliven Therapeutics, Inc. | Chief Medical Officer | Sale+OE10b5-1 | 20,000 | $25.07 | $501,478.00 | - | -3.2% | -30.7% |